Press release
Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Outlook and Strategic Analysis 2026 to 2035
Antibody-drug Conjugates (ADCs) CMO and CDMO Market
Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size is valued at USD 9.23 Bn in 2025 and is predicted to reach USD 30.63 Bn by the year 2035 at a 13.0% CAGR during the forecast period for 2026 to 2035.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com//request-sample/3639
ADCs are targeted anticancer agents that consist of a monoclonal antibody, a cytotoxic drug with highly potent activity, and specialized linkers. The production of antibody-drug conjugates is associated with highly complicated processes that include antibody production, linker synthesis, payload manufacturing, conjugation, purification, fill-finish, and quality testing.
Therefore, many pharma and biotech companies prefer to outsource their manufacturing capabilities to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). A large number of ADC candidates undergoing clinical trials and an increasing number of approvals for targeted oncology drugs drive the ADCs CMO and CDMO market. Many biopharma companies prefer to outsource manufacturing operations to minimize their investments, expedite development processes, and use advanced conjugation technologies.
In addition, the continuous increase in investment for high-potency manufacturing facilities, growing capabilities of producing biologics, and increasing partnerships between biotechnology and CDMOs are some other factors fueling the growth of the market. However, strict regulatory environment, complicated manufacturing process, and the requirement of specialized facilities may hamper market growth. Despite that, the rising demand for personalized cancer therapies and growing development pipeline for ADCs are anticipated to create lucrative opportunities in the coming years.
List of Prominent Players in the Antibody-drug Conjugates (ADCs) CMO and CDMO Market:
• Lonza Group AG
• Catalent Inc.
• Samsung Biologics Co., Ltd.
• WuXi Biologics
• AGC Biologics
• Recipharm AB
• Sterling Pharma Solutions
• Piramal Pharma Solutions
• Cerbios-Pharma SA
• Axplora (formerly Novasep)
• Ajinomoto Bio-Pharma Services
• BioDuro-Sundia
• AbbVie Contract Manufacturing
• BSP Pharmaceuticals S.p.A.
• MilliporeSigma (Merck KGaA)
• Sterling Pharma Solutions
• Cambrex Corporation
• Thermo Fisher Scientific Inc. (Patheon)
• CordenPharma International
• MabPlex International Co., Ltd.
• Resonac Corporation
• SK pharmteco
• Fujifilm Diosynth Biotechnologies
• Simtra BioPharma Solutions
• Bora Biologics
Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com
Market Dynamics:
Drivers:
There is considerable growth witnessed in the market for ADCs CMO and CDMO owing to the rising number of ADCs under development and the increased commercialization of oncology drugs targeting specific diseases. There is an increase in the outsourcing of manufacturing of ADCs by pharma companies to specialized CMOs and CDMOs that have experience in manufacturing biologic drugs, HPAPIs, ADC conjugation, and fill finish technologies. There is also an increase in the investment in developing oncology drugs, increased capacity for producing biologics, and approvals for ADC therapies that will drive market growth. Furthermore, strategic partnerships between biotech companies and manufacturing companies are anticipated to drive market growth in the forecast period.
Challenges:
The manufacturing of ADCs demands highly specific production facilities, stringent containment procedures, and adherence to stringent regulations of the global nature. The conjugation process entails the use of extremely toxic cytotoxic agents, thus demanding rigorous quality control measures and trained staff. Apart from this, there is the issue of setting up specific infrastructure for the manufacturing of ADCs that comes at the cost of considerable investment.
Regional Trends:
The North American region represented the maximum market share in terms of ADCs CMO and CDMO in 2025 due to the presence of a strong biopharmaceutical industry, rise in oncology research activities, and presence of leading contract manufacturing organizations in the region. Growing investment in biologics manufacturing, advanced regulatory framework, and rise in approvals of ADCs continue to propel the market in the region. Moreover, the collaboration of pharmaceutical firms with CDMOs is enhancing manufacturing capacity in the US and Canada.
The Asia-Pacific region will witness the highest growth rate during the forecast period. Rising investment in manufacturing infrastructure of biologics, increase in outsourcing activities by global pharmaceutical firms, low manufacturing costs, and supportive government policies will drive the market in countries like China, South Korea, Japan, Singapore, and India. Expansion of contract development and manufacturing facilities will further propel the growth of the market in the region.
Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3639
Segmentation of Antibody-drug Conjugates (ADCs) CMO and CDMO Market-
By Service Type (The Workflow)
• cGMP Conjugation & Drug-Linker Production
• Fill-Finish Services
• Process Development & Analytical Testing
By Process Component (The Molecule)
• Antibody Manufacturing
• HPAPI / Cytotoxic Payloads
• Linkers
By Linker Technology
• Cleavable Linkers
• Non-Cleavable / Site-Specific Linkers
By Phase of Development
• Pre-Clinical & Phase I/II
• Commercial Manufacturing
By Target Indication (Disease Area)
• Solid Tumors (Breast, Lung, etc.)
• Hematologic Cancers (Myeloma/Lymphoma)
• Non-Oncology (Autoimmune/Infectious)
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/antibody-drug-conjugates-cmo-and-cdmo-market-/3639
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antibody-drug Conjugates (ADCs) CMO and CDMO Market Growth Outlook and Strategic Analysis 2026 to 2035 here
News-ID: 4578982 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Hotel Channel Management Software Market Industry Insights and Future Projection …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Hotel Channel Management Software Market Size, Share & Trends Analysis Report by Deployment Type (Cloud-based, On-premises), by Property Size (Small, Medium, Large), by Functionality (Inventory Management, Reservation Management, Rate Management, Distribution Management, Analytics and Reporting), by Integration (Property Management System (PMS), Distribution Platforms, Central Reservation Systems (CRSs), Revenue Management Systems (RMSs)) Market Outlook And Industry…
Skin Virome Profiling Market Outlook and Revenue Forecast 2026 to 2035
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Skin Virome Profiling Market Size, Share & Trends Analysis Report By Technology (Next-Generation Sequencing, PCR-Based Methods, Microarray, Others), By Application (Clinical Diagnostics, Research, Personalized Medicine, Others), By End-User (Hospitals & Clinics, Research Institutes, Diagnostic Laboratories, Others), By Sample Type (Swab, Biopsy, Others),- Market Outlook And Industry Analysis 2035"
Skin Virome Profiling Market Size is valued…
AI-Based Microbiome Platforms Market Top Players- GE Viome Life Sciences, Eagle …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global AI-Based Microbiome Platforms Market Size, Share & Trends Analysis Report By Microbiome Type (Gut Microbiome, Skin Microbiome, Oral Microbiome, And Environmental Microbiome), Deployment Mode (Cloud-Based, On-Premises, And Hybrid Models), Application (Drug Discovery & Development, Precision Medicine & Personalized Nutrition, Clinical Diagnostics, Consumer Microbiome & Wellness Platform, And Others), End-User (Pharmaceutical & Biotechnology Companies, Clinical &…
Artificial intelligence in robotics market Key Players Analysis - NVIDIA Corpora …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Artificial intelligence in robotics market Size, Share & Trends Analysis Report By Offering (Hardware, and Software), Deployment Mode (Cloud and On-premises), Robots (Industrial Robots, and Service Robots), Technology (Machine Learning, Natural Language Processing, Computer Vision, Context Aware Computing, Edge Computing, and Others), End-user (Automotive, Manufacturing, Transportation & Logistics, Healthcare, Retail, Aerospace, Military & Defense, Agriculture,…
More Releases for ADC
ADC Market: Transforming Cancer Treatment
The global market for antibody-drug conjugates (ADCs) was valued at US$ 11.32 billion in 2023 and is expected to reach US$ 27.37 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.23% from 2024 to 2033. This growth is primarily driven by the increasing prevalence of cancer and the growing demand for safe and effective treatments.
Antibody Drug Conjugates: A Growing Force in Cancer Treatment and Market Expansion
Key…
With Knockout ADC Innovations, Creative Biolabs Took Center Stage at the 2024 Wo …
Creative Biolabs wrapped up a successful show at the 15th Annual World ADC San Diego in the beginning of November, where its third year of participation, highlighting its dedication to the advancement of antibody-drug conjugate (ADC) technology.
New York, USA - November 13, 2024 - Creative Biolabs seized the spotlight at Booth 313 by offering groundbreaking solutions across the entire ADC development spectrum, which demonstrate their unrivaled expertise and dedication to…
Showing Off Their ADC Game: Creative Biolabs Hits the 15th Annual World ADC Summ …
From November 4, Creative Biolabs will be back at the 15th Annual World ADC Summit in San Diego, marking its fourth year at the leading global gathering featuring innovative conjugates.
New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg
"2023…
ADC Drugs For Breast Cancer Treatment
Breast cancer is the malignant tumor with the highest morbidity and mortality among women worldwide. At present, the main therapeutic methods include surgery, chemotherapy, radiotherapy, endocrine therapy and targeted therapy, etc. The development and marketing of new drugs have far-reaching significance in improving the survival of breast cancer patients and changing the pattern of breast cancer treatment.
On February 24, 2023, The NMPA approved Enhertu, an injectable drug developed jointly by…
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Succe …
Analog-to-Digital Converters Market by Product (Ramp ADC, Integrating ADC, Successive Approximation ADC, Delta-sigma ADC, and Others (Pipelined/Flash ADC)), and Application (Consumer Electronics and Industrial) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Full Report : https://www.alliedmarketresearch.com/analog-to-digital-converters-market
Increasing disposable income and technological advancements supplement the analog-to-digital converters market. However, complex design of the ADC hampers this market growth. On the other hand, encouragement in digitization of work processes by government in emerging economies,…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
